📰 Nsclc News
Page 45 - Nsclc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nsclc. Real-time updates on events, politics, business and more.
December 6, 2022
- Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC - - Safety and tolerability
December 6, 2022
Ft. Myers, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- A clinical study conducted with participation by Florida Cancer Specialists & Research Institute,...
November 25, 2022
The drug was not approved for the treatment of patients with previously treated locally advanced or metastatic nonsmall cell lung cancer harboring HER2 exon 20 insertion mutations.
November 15, 2022
The warning follows an FDA inspection at the Phoenix-based Abraxis BioScience plant that found contamination hazards in its manufacturing process.
October 27, 2022
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Phase II SUMMIT basket trial of neratinib for EGFR exon 18-mutant non-small cell lung cancer
October 5, 2022
The new PD-1 inhibitor from China yielded positive results in a phase 3 trial, and a further trial in the US is now planned to bolster prospects for FDA approval.
September 26, 2022
Consequences of cancer cachexia can include skeletal muscle loss, fatigue, functional impairment, worse quality of life, and worse survival.
September 23, 2022
Most FDA panelists expressed doubts about the strength of evidence regarding the benefits of the experimental drug, especially given available therapies.
September 22, 2022
LUND, Sweden, Sept. 22, 2022 /PRNewswire/ -- Cantargia (Cantargia AB) (Nasdaq: CANTA) (Stockholm: CANTA) today reported that the first patient has been treated in a new arm of the phase Ib clinical
September 22, 2022
NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company...